Indications |
Oral Short-term management of anxiety Adult: 50-100 mg 4 times daily. Renal impairment: Moderate-severe impairment: Reduce dose by 50%. Hepatic impairment: Reduce total daily dose by 33%. Oral Pruritus in acute and chronic urticaria and dermatosis Adult: Initially, 25 mg at night increased if required up to 25 mg 3-4 times daily. Child: 6 mth-6 yr: 5-15 mg daily, increased to 50 mg/day in divided doses; >6 yr: Initially, 15-25 mg/day, increased up to 50-100 mg/day. Renal impairment: Moderate-severe impairment: Reduce dose by 50%. Hepatic impairment: Reduce total daily dose by 33%. Oral Adjunct to pre- or post-operative sedation Adult: 50-100 mg. Child: 600 mcg/kg. Renal impairment: Moderate-severe impairment: Reduce dose by 50%. Hepatic impairment: Reduce total daily dose by 33%. Intramuscular Prompt control of anxiety or agitation Adult: Initially, 50-100 mg, may repeat every 4-6 hr if necessary. Renal impairment: Dose adjustment is required. Hepatic impairment: Dose adjustment is required. Incompatibility: Incompatible with aminophylline, benzylpenicillin salts, chloramphenicol sodium succinate, dimenhydrinate, liposomal doxorubicin hydrochloride, thioridazine and some soluble barbiturates. |
Contraindications |
Porphyria, neonates, pregnancy, lactation. |
Warnings / Precautions |
Renal and hepatic impairment; narrow-angle glaucoma; epilepsy; prostatic hypertrophy; bladder neck obstruction; asthma; COPD. May impair ability to drive or operate machinery. |
Adverse Reactions |
CNS depression, paradoxical CNS stimulation, dry mouth, thickened respiratory secretions, constipation, blurring of vision, tachycardia, GI disturbances, headache, hypotension, tinnitus. |
Overdose Reactions |
Excessive sedation, hypotension (rare). Symptomatic and supportive treatment. Empty stomach immediately by inducing emesis or by gastric lavage. IV fluids and norepinephrine or metaraminol (do not use epinephrine) if hypotension. Haemodialysis or peritoneal dialysis is probably not effective. |
Drug Interactions |
Masks ototoxicity of aminoglycoside antibiotics. Potentially Fatal: Potentiates CNS depression by barbiturates, hypnotics, opioid analgesics, sedatives and neuroleptics. MAOIs, atropine, and TCAs potentiate antimuscarinic effects. See Below for More hydroxyzine Drug Interactions |
Food Interactions |
Increased CNS depression with alcohol. |
Mechanism of Actions |
Hydroxyzine blocks histamine H1-receptors on effector cells of the GI tract, blood vessels and respiratory tract; a sedating anihistamine with antimuscarinic and significant sedative properties. It also possesses skeletal muscle relaxing, bronchodilator, antiemetic and analgesic properties. Absorption: Absorbed rapidly from the GI tract (oral). Metabolism: Converted to cetirizine (has antihistaminic properties). Excretion: 20 hr (elimination half-life). |
Administration |
May be taken with or without food. |
Storage Conditions |
Intramuscular: Store at 15-30°C. Oral: Store at 15-30°C. |
ATC Classification |
N05BB01 - hydroxyzine ; Belongs to the class of diphenylmethane derivatives anxiolytics. Used in the management of anxiety, agitation or tension. |
Storage |
Intramuscular: Store at 15-30°C. Oral: Store at 15-30°C. |
Available As |
|
Hydroxyzine
Post Review about Hydroxyzine Click here to cancel reply.
Hydroxyzine Containing Brands
Hydroxyzine is used in following diseases
Drug - Drug Interactions of Hydroxyzine
Latest News
- FDA approves Ruconest for treatment of hereditary angioedema
- FDA recommend against aspirin to prevent First Heart Attacks
- FDA approves Pomalyst (pomalidomide) for advanced multiple myeloma
- FDA approves three new drug treatments for type 2 diabetes
- Long-term consequences of vaginal delivery on the pelvic floor
No comments yet.